Oxaloacetate ( DrugBank: Oxaloacetate )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| 11 | Myasthenia gravis | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01741701 (ClinicalTrials.gov) | December 2012 | 1/12/2012 | A Pilot Study of Oxaloacetate in Subjects With Treated PD | A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD) | Parkinson's Disease | Drug: Oxaloacetate (OAA);Drug: Placebo | University of Kansas Medical Center | Terra Biological LLC | Completed | 30 Years | N/A | All | 33 | Phase 2/Phase 3 | United States |
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04965987 (ClinicalTrials.gov) | October 2021 | 10/6/2021 | Oxaloacetate in Myasthenia Gravis | A Phase I, Double-Blind, Pilot Study of Oxaloacetate in Myasthenia Gravis | Myasthenia Gravis | Drug: Oxaloacetate;Drug: Placebo | University of Kansas Medical Center | Terra Biological LLC | Not yet recruiting | 18 Years | N/A | All | 12 | Phase 1 | United States |